hPDL1/CT26 I. Background Programmed Cell Death Protein 1(PD-1) ,一种在激活的 T 细胞上表达的受体,与其 配体 PD-L1 和 PD-L2 结合,负向调节免疫反应。 PD-1 配体存在于大多数癌症中,PD- 1:PD-L1/2 相互作用会抑制 T 细胞活性,并使癌细胞逃避免疫监视。 PD1/PDL1 信号转导通 路是肿瘤免疫抑...
肿瘤细胞表达的PD-L1可结合T细胞表面的PD-1,使T细胞失去识别和打击肿瘤细胞的能力。为研究PD-1基因敲除的T细胞治疗结肠癌的有效性,研究人员采用CT26细胞(结肠
Strain Information Cell Line CT26-hPD-L1/hCLAUDIN 18.2 Cat. NO. NMC-230112 Model Description PD-L1 and CLAUDIN 18.2 gene humanized CT26 cell line Strain State Construction *Literature published using this strain should indicate: CT26-hPD-L1/hCLAUDIN 18.2 cell line (Cat. NO. NMC-230112) was ...
1可结合到T细胞表面的PD1,使T细胞失去识别和打击肿瘤细胞的能力。为研究PD1基因敲除的T细胞治疗结直肠癌的有效性,研究人员采用CT26细胞(结直肠癌细胞株)、小鼠等实验材料进行相关实验。下列叙述错误的是( ) A. 肿瘤细胞表面的PDL1与T细胞表面的PD1结合,促进T细胞的活化 B. 可用基因敲除技术敲除小鼠T细胞中PD1基因...
CT26 MC38 EL4 PD-1 PD-L1 genO-hPD‑1/hCTLA‑4 The genO‑hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice. genO-hPD‑1/hGITR/hGITRL The ...
PD-L1 and CLAUDIN 18.2 gene humanized CT26 cell line 品系状态 构建中 *使用本品系发表的文献需注明: CT26-hPD-L1/hCLAUDIN 18.2 cell line (Cat. NO. NMC-230112) was purchased from Shanghai Model Organisms Center, Inc.. 相关品系 MC38-hPD-L1/hCLAUDIN 18.2 细胞系名称:MC38-hPD-L1/hCLAUD...
这里所说的两类免疫治疗，第一大类是以PD-1/L1抑制剂为代表的，驱动内源性免疫细胞的内源免疫治疗。这种方法很大程度上依赖于已经存在的特异性识别癌细胞的CD8+T细胞，通过免疫治疗增强其抗肿瘤活性。但并不是所有的癌种都存在足够供内源性细胞识别的抗原，有的癌种还会利用MHC下调来逃避免疫。这种情况下便出现了...
同时采用小鼠结肠腺癌CT26细胞系肝转移模型,通过肿瘤细胞脂质体转染PD-L1反义寡核苷酸、腹腔注射PD-L1反义寡核苷酸两种方式,观察PD-L1反义寡核苷酸处理后结肠癌CT26细胞肝脏转移癌结节数量的变化。 结果:1. 55例大肠癌组织中,PD-L1阳性表达29例(29/55,52.7%),明显高于对照肠黏膜(1/10,10%),χ~2检验,差异具...
PD-L1/CD86基因双人源化的CT26结肠癌细胞系 品系状态 表达验证完成 *使用本品系发表的文献需注明: CT26-hPD-L1/hCD86 cell line (Cat. NO. NM-S24A-TM43) was purchased from Shanghai Model Organisms Center, Inc.. 验证数据 Fig1. Human/mouse CD86 expression in vitro cultured cells of CT26-hPD-...
we provide a comprehensive overview of the pleiotropic roles of ILC2s in diklerent tumor settings. Furthermore, we discuss how diklerent therapeutic approaches targeting ILC2s could improve the eklicacy of current tumor immunotherapies.Immune checkpoint inhibitors (ICI) such as PD-1/PD-L1 antibodies...